Based on real-world data, Johnson & Johnson (NYSE:JNJ) announced Wednesday its prostate cancer therapy Erleada (apalutamide) ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, ...

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis ...

Radiopharmaceuticals have been used to treat patients with prostate cancer for decades, but experts say there is more to ...

Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

Opens in a new tab or window Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived significantly longer when they received enzalutamide ...

Zydus Lifesciences share price trading maginally lower in the opening trade on October 3 despite the company received ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and ...

Abiraterone acetate plus prednisone and enzalutamide improve overall survival (OS) and radiological progression-free survival (rPFS) in docetaxel-pretreated patients. Abiraterone acetate plus ...